4D Molecular Therapeutics FDMT

Mr. Kristian F. Humer, on March 25, 2026, the Board of Directors of 4D Molecular Therapeutics, Inc. appointed Kristian Humer as the Company's Principal Accounting Officer, effective immediately. Mr. Humer, age 51, has served as the Company's Chief Financial Officer and Principal Financial Officer since November 2025. Mr. Humer previously served as the Chief Financial Officer at Foghorn Therapeutics, Inc., a biotechnology company, from April 2024 to November 2025. From July 2021 to September 2023, Mr. Humer served as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc., a biotechnology company. From January 2010 to July 2021, Mr. Humer served in various roles at Citigroup Global Markets Inc., including most recently as Managing Director in the Healthcare Investment Banking Group from December 2016 to July 2021. Mr. Humer holds an MBA degree from Duke University's Fuqua School of Business and a BA (Hons) degree in Accounting & Economics from the University of Reading. Mr. Kristian F. Humer stepped down as Principal Accounting Officer effective March 25, 2026 and Continue as Vice President, Finance and Controller) (Mr. Humer succeeds Ashoo Gupta, who continues to serve as the Company's Vice President, Finance and Controller.

The Board of Directors of the Company appointed David Kirn, M.D., the Company's current Chief Executive Officer, as the President and Chief Executive Officer of the Company. David Kirn, M.D., is our co-founder and has served as our Chief Executive Officer and served on our board of directors since our inception in 2013. Dr. Kirn previously served as the Executive Chairman of our board until August 2020 when John Milligan, Ph.D. assumed the position. Dr. Kirn is Adjunct Professor of Bioengineering and Molecular & Cellular Biology at U.C. Berkeley and is the co-founder and on the board of directors of the U.C. Berkeley Life Sciences Entrepreneurship Center. He previously served as Executive Chairman of the board of Ignite Immunotherapy Inc., where he was a co-founder. Dr. Kirn held senior development positions at Onyx Pharmaceuticals and Celgene, and he was a senior project leader and advisor on viral vector gene therapeutics and cancer immunotherapy for over 10 years with numerous companies, including Biogen, Novartis, Cell Genesys, Pfizer and Bayer. Dr. Kirn received a B.A. in Physiology (Departmental Citation; Phi Beta Kappa) from U.C. Berkeley in 1985, an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women's Hospital. He served as Chief Medical Resident at the Harvard-affiliated WRVA hospital. He completed medical oncology and clinical research fellowships at U.C. San Francisco, and he completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. In 2013, he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.

Fariborz Kamal, Ph.D., has served as our President and Chief Operating Officer since September 2022 and previously served as our Chief Operating Officer from February 2020 to September 2022 and as our Chief Technical Officer from October 2018 to February 2020. Dr. Kamal previously served as Senior Vice President of Quality and Regulatory CMC for AveXis Inc., a gene therapy company, from May 2017 through August 2018. Prior to AveXis, Dr. Kamal served as the Vice President of Quality for Juno Therapeutics from May 2015 through April 2017 and prior to that Dr. Kamal served as the Vice President of Quality and Regulatory CMC for Intermune Inc. from January 2013 through March 2015. Dr. Kamal received his B.S. in Chemistry from San Jose State University in 1986. Dr. Kamal received his M.Sc. in Chemistry from The American University in 2000. He received his Ph.D. in Chemistry from The American University in 2003. Effective January 1, 2026, Dr. Kamal resigned as President.

John F. Milligan, Ph.D., has served as Executive Chairman of our board of directors since August 2020. Dr. Milligan previously served as the President and Chief Executive Officer of Gilead Sciences, Inc. from March 2016 until February 2019, and as its President and Chief Operating Officer from May 2008 until March 2016, served on the board of directors of Gilead Sciences, Inc. from March 2016 until December 2018, and spent a total of 29 years at Gilead in various roles since 1990. Prior to joining Gilead, Dr. Milligan was a postdoctoral research fellow at the University of California San Francisco Medical Center. Dr. Milligan has served on the board of directors of Pacific Biosciences of California, a publicly traded biotechnology company, since July 2013, Kailera Therapeutics, a publicly traded clinical-stage biopharmaceutical company, since October 2024, and TurnCare, Inc., a privately held patient-support technology company, since December 2023. He also served as the Chair of the Board of Trustees of Ohio Wesleyan University from October 2010 to June 2025. Dr. Milligan received his B.A. in Chemistry from Ohio Wesleyan University in 1983 and his Ph.D. from the University of Illinois at Urbana-Champaign in 1988.

Susannah Gray, MBA, has served as a member of our board of directors since July 2020. Ms. Gray served as the Executive Vice President of Finance and Strategy of Royalty Pharma Management, LLC, a buyer of pharmaceutical royalties and a funder across the biopharmaceutical industry, and in various other similar roles from 2005 until 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities, Inc. (predecessor of JP Morgan Securities, Inc.). Ms. Gray currently serves on the board of directors of AnaptysBio, Inc., a publicly traded clinical-stage biotechnology company, since March 2026, Theravance BioPharma, Inc., a publicly traded biopharmaceutical company, since February 2023, and Maravai LifeSciences Holdings, Inc., a publicly traded biotechnology company, since December 2020. She also serves on the board of directors of several private companies and organizations, including Hidden Pigeon Company, StreetSquash, and the German Marshall Fund. Ms. Gray is also a trustee of Wesleyan University and serves as a Governor of the Colby College Museum of Art. Ms. Gray previously served on the board of directors of Morphic Holding, Inc., a publicly traded biopharmaceutical company, from April 2021 until its acquisition in August 2024, and Apria, Inc., a privately held healthcare company, from May 2021 until its acquisition in March 2022. From March 2021 until February 2025, Ms. Gray was a member of the board of directors of BioSplice Therapeutics, Inc., a privately held pharmaceutical company. Ms. Gray received a B.A. from Wesleyan University in 1982 and an M.B.A. from Columbia University in 1990.

Charles P. Theuer, M.D., Ph.D., has served as a member of our board of directors since December 2015. Dr. Theuer has served as Chief Medical Officer at Halozyme, Inc., since October 2024. He previously served as President and Chief Executive Officer at Tracon Pharmaceuticals, Inc., from June 2006 until July 2024 and Chief Medical Officer at TargeGen, Inc. until June 2006. He previously served on the board of directors of Tracon Pharmaceuticals, Inc. from June 2006 until July 2024 and Oncternal Therapeutics Inc., from May 2018 until July 2025. Dr. Theuer received a B.S. in Life Sciences from the Massachusetts Institute of Technology in 1985. He received his M.D. from U.C. San Francisco in 1989. He received his Ph.D. in Environmental Health Science from U.C. Irvine in 2002.

Jacob Chacko, M.D., MBA, has served as a member of our board of directors since March 2019. Dr. Chacko has served as Chief Executive Officer of ORIC Pharmaceuticals, Inc., a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, since May 2018. Prior to ORIC, Dr. Chacko served as Chief Financial Officer of Ignyta, Inc., a publicly traded precision oncology company, from May 2014 until February 2018 when Ignyta was acquired by Roche Holdings, Inc. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital from August 2008 until May 2014. From 2002 until 2003, Dr. Chacko was a consultant serving healthcare clients at McKinsey & Company. Dr. Chacko has served as chairman of the board of directors of Bright Peak Therapeutics, an oncology company, since November 2021. He also served on the board of directors of Turning Point Therapeutics, Inc., a publicly traded biotechnology company, from November 2018 until March 2021, RentPath Inc., a digital media company, from 2011 until 2014, Envision Pharmaceutical Services, LLC from 2013 until 2014, Bonti, Inc., a biotechnology company, from February 2018 until October 2018 and the Packard Children's Health Alliance at the Lucile Packard Children's Hospital Stanford from 2013 until June 2017. Dr. Chacko currently chairs the Western Regional Selection Committee for the Marshall Scholarship. Dr. Chacko concurrently received his M.D. from U.C. Los Angeles and his M.B.A. from Harvard Business School. Dr. Chacko received a M.Sc. from Oxford University as a Marshall Scholar.

Shawn Cline Tomasello, MBA, has served as a member of our board of directors since November 2020. Ms. Tomasello was CEO and board member of CoRegen, Inc. from December 2024 until April 2025. She served as Chief Commercial Officer of Kite Pharma from December 2015 to July 2018. Before that, Ms. Tomasello served as the Chief Commercial Officer of Pharmacyclics, LLC from August 2014 to August 2015. She has served on the boards of several publicly traded biotechnology companies including Cabaletta Bio, Inc. since July 2023, as well as the board of the privately held biotechnology company Centrexion Therapeutics Corporation since June 2017, and previously served on the boards of Orna Therapeutics, Inc., a privately held biotechnology company, from September 2022 until March 2024 (acquired), TCR2 Therapeutics, Inc. from February 2021 until June 2023 (acquired), AlloVir, Inc. from March 2022 until March 2025 (acquired), and Gamida-Cell Ltd. from March 2019 until May 2024 (restructured). Ms. Tomasello previously served on the board of several publicly traded biotechnology companies, including UroGen Pharma Ltd. from July 2018 to June 2022 and Mesoblast Ltd. from July 2018 to August 2022. Ms. Tomasello received her undergraduate degree in marketing from the University of Cincinnati in 1982 and her MBA from Murray State University in Kentucky in 1989.

Nancy Miller-Rich has served as a member of our board of directors since November 2020. She has served as a consultant and advisor to various pharmaceutical and biotechnology companies since September 2017. Previously, Ms. Miller-Rich served in a number of leadership roles at Merck & Co., Inc. and, prior to the merger of the two companies, at Schering-Plough Corporation, including most recently as Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from November 2013 to September 2017 and as Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from January 2007 to November 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. Ms. Miller-Rich has served on the board of directors of several publicly traded biotechnology companies, such as, Aldeyra Therapeutics, Inc. since January 2020, Intercept Pharmaceuticals, Inc. from April 2018 to October 2023, and Kadmon Holdings, Inc. from October 2020 to November 2021. She has also served on the board of directors of private biotechnology companies Attralus, Inc. since July 2020 and BioTheryX from August 2021 until April 2023. She received her undergraduate degree in Business Administration, Marketing, from Ithaca College in New York in 1981.

Theresa Janke is a co-founder and has served in positions of increasing responsibility since our inception. She served as our Chief Operating Officer from April 2018 until February 2020, at which point she began serving as our Chief Strategy Officer. Ms. Janke previously served in various consulting roles in 2013-2014 including: Senior Director of Corporate Projects & Alliance Management at SillaJen, Inc. (formerly Jennerex Biotherapeutics Inc.), a biotech company focused on engineering and developing oncolytic immunotherapeutics, and Director, Clinical Research & Development-Strategy and Alliances at Celgene Corporation, a global biopharmaceutical company. Prior to that, she served in positions of increasing responsibility, including Director of Clinical Operations, at Jennerex Biotherapeutics Inc., an oncolytic immunotherapy biotech company, from 2007 through 2013. She was a co-founder and served on the board of directors of Ignite Immunotherapy Inc., a private biotech company focused on oncolytic cancer vaccine discovery and development. Ms. Janke received a B.S. in Biopsychology from the U.C. Santa Barbara in 1996.

Christopher Simms has served as our Chief Commercial and Business Officer since December 2025 and served as our Chief Commercial Officer from September 2024 until December 2025. Mr. Simms previously served as Chief Commercial Officer at IVERIC bio, Inc., a biopharmaceutical company, from August 2021 to July 2024. From November 2017 to July 2021, Mr. Simms served in various roles at Novartis AG, a multinational pharmaceutical corporation, most recently as VP, Head of US Ophthalmics. Mr. Simms holds an MBA degree from York University, Schulich School of Business, and a Bachelor of Commerce from Memorial University of Newfoundland.

Scott Bizily, J.D., Ph.D., has served as our Chief Legal Officer and Corporate Secretary since September 2021 and as our Chief Compliance Officer since December 2021. Dr. Bizily also served as our Chief Human Resources Officer from June 2022 until January 2024. Dr. Bizily previously served as General Counsel at Synthego Corporation, a privately held life sciences tools and services company specializing in genome engineering, from January 2019 to September 2021 and as Director, Corporate Counsel at BioMarin Pharmaceutical Inc., a publicly held biopharmaceutical company specializing in rare diseases, from 2010 to 2019. From 2005 to 2007, Dr. Bizily practiced in patent litigation at Weil, Gotshal & Manges LLP, and from 2007 to 2009 in life sciences licensing and corporate partnering at Cooley LLP. Dr. Bizily was a postdoctoral fellow at University of Pennsylvania from 2001 to 2002. He received his B.A. in Ecology and Evolutionary Biology from Princeton University in 1994, his Ph.D. in Genetics from the University of Georgia in 2001, and his J.D. from the University of Pennsylvania Carey Law School in 2005.

On September 30, 2025, the Board of Directors of 4D Molecular Therapeutics, Inc. appointed Ashoo Gupta as Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately. Mr. Gupta, age 49, has served as the Company's Vice President, Finance & Controller since June 2024. Prior to joining the Company, Mr. Gupta served as Vice President of Finance and Corporate Controller at Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, from September 2023 to June 2024. From March 2019 to June 2023, Mr. Gupta served as Executive Director of Accounting and Corporate Controller at Myovant Sciences, Inc., a biopharmaceutical company. Mr. Gupta holds a Bachelor of Commerce from University of Mumbai and is a Certified Public Accountant.

Effective as of January 5, 2026, the Board appointed Glenn Sblendorio to the Board as a Class I director. Mr. Sblendorio most recently was Chief Executive Officer and member of the Board of Directors of IVERIC bio, Inc., a biopharmaceutical company, from July 2017 to its acquisition by Astellas Pharma, Inc. in July 2023. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. In addition, from 1998 through 2000, Mr. Sblendorio served as a Managing Director of MPM Capital Advisors. Mr. Sblendorio currently serves as Chair of the Board of Directors of Mineralys Therapeutics, Inc. and a member of the Board of Directors of Amicus Therapeutics, Inc. Previously, he served as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. until it was acquired in November 2023. Mr. Sblendorio received his B.B.A. from Pace University, his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program.